1971
Preliminary clinical trials and clinical pharmacologic studies with 5-(3,3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196) given orally.
Vogel C, DeVita V, Denham C, Foley H, Field R, Carbone P. Preliminary clinical trials and clinical pharmacologic studies with 5-(3,3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196) given orally. Cancer Chemotherapy Reports 1971, 55: 159-65. PMID: 5118685.Peer-Reviewed Original Research
1970
The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.
Vogel C, Denham C, Waalkes T, DeVita V. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs. Cancer Research 1970, 30: 1651-7. PMID: 5457935.Peer-Reviewed Original ResearchConceptsPhysiological disposition